Rolando Gutierrez-Esteinou - Mar 14, 2023 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Chief Medical Officer
Signature
/s/ Ryan Barrett, Attorney-in-fact
Stock symbol
ATAI
Transactions as of
Mar 14, 2023
Transactions value $
$0
Form type
4
Date filed
3/16/2023, 08:22 PM
Previous filing
Mar 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Stock Option Award $0 +500K $0.00 500K Mar 14, 2023 Common Shares 500K $1.18 Direct F1
transaction ATAI Restricted Stock Unit Award $0 +200K $0.00 200K Mar 14, 2023 Common Shares 200K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.